Cytokinetics Announces Proposed Public Offering of Convertible Senior Notes
November 06, 2019 16:05 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it expects to sell, subject to market and other conditions, an aggregate...
Cytokinetics to Participate in the Credit Suisse 28th Annual Healthcare Conference
November 05, 2019 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research &...
Cytokinetics Reports Third Quarter 2019 Financial Results
October 31, 2019 16:00 ET
|
Cytokinetics, Incorporated
Enrollment Completed in GALACTIC-HF with More than 8,200 Heart Failure Patients; Second Interim Analysis Expected in Q1 2020 Data from Phase 1 Study of CK-274 Support Progression; Phase 2 Clinical...
Cytokinetics to Announce Third Quarter Results on October 31, 2019
October 24, 2019 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on October 31, 2019 at...
Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting
October 04, 2019 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional analyses of FORTITUDE-ALS (Functional Outcomes in a Randomized...
Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 26, 2019 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting
September 26, 2019 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from FORTITUDE-ALS (Functional Outcomes in...
Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals
September 25, 2019 07:30 ET
|
Cytokinetics, Incorporated
Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular or Neuromuscular Diseases Deadline for Applications is November 15th, 2019 SOUTH SAN FRANCISCO,...
Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23ʳᵈ Annual Scientific Meeting
September 16, 2019 07:30 ET
|
Cytokinetics, Incorporated
Pharmacokinetic/Pharmacodynamic Relationship in Humans Similar to Preclinical Findings Data Support Progression to Phase 2 Clinical Trial in Patients with Obstructive Hypertrophic Cardiomyopathy to...
Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting
September 06, 2019 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two poster presentations at the 23rd Annual Heart Failure Society of America...